Status:
RECRUITING
Corneal Crosslinking for Treatment of Corneal Neovascularization
Lead Sponsor:
Price Vision Group
Collaborating Sponsors:
Cornea Research Foundation of America
Conditions:
Corneal Neovascularization
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Eligibility Criteria
Inclusion
- 18 years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
- Signed written informed consent.
Exclusion
- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study
Key Trial Info
Start Date :
May 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2026
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04787471
Start Date
May 3 2021
End Date
September 15 2026
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Price Vision Group
Indianapolis, Indiana, United States, 46260